Cryoport, Inc. (CYRX) Stock Price & Analysis
Cryoport, Inc. (CYRX) fell 4.12% to USD 15.37 as of July 25, 2026 at 11:16 UTC, according to Nexqual real-time market data.
CYRX last closed at USD 16.03; the session ranged USD 15.33–16.59 on volume of 518,844 shares. Market capitalization is $774.68M, with a 52-week range of USD 6.69–16.89 (NCM). Source: Nexqual, July 25, 2026 at 11:16 UTC.
Key Statistics (as of July 25, 2026 at 11:16 UTC)
| Price | USD 15.37 |
|---|---|
| Change | ▼ 4.12% (down) |
| Previous Close | USD 16.03 |
| Open | USD 16.59 |
| Day Range | USD 15.33 – 16.59 |
| 52-Week Range | USD 6.69 – 16.89 |
| Volume | 518,844 shares |
| Market Cap | $774.68M |
| Exchange | NCM |
Technical Analysis (CYRX)
Nexqual's technical model rates CYRX "NEUTRAL" based on 3 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 11:16 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 44.42 (neutral) |
| vs SMA50 | Above (USD 15.19) |
| MACD | 0.29 (positive) |
Analyst Ratings (CYRX)
Wall Street analysts rate CYRX "Strong Buy" based on 9 analysts, with a mean price target of USD 16.17 (range USD 12–20), per Nexqual as of July 25, 2026 at 11:16 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 16.17 |
| High Target | USD 20 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 8 / 1 / 0 |
Earnings (CYRX)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.18 |
| Revenue Estimate | $48.21M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.19 vs est -0.19 ▲ beat |
| 2025-12-31 | USD -0.17 vs est -0.21 ▲ beat |
| 2025-09-30 | USD -0.13 vs est -0.19 ▲ beat |
| 2025-06-30 | USD -0.24 vs est -0.22 ▼ miss |
Source: Nexqual, July 25, 2026 at 11:16 UTC.
Financials & Fundamentals (CYRX)
| Total Revenue | $182.94M |
|---|---|
| Revenue Growth (YoY) | +16.50% |
| Gross Margin | +47.19% |
| Operating Margin | -20.08% |
| Profit Margin | +43.59% |
| ROE | -8.20% |
| Debt / Equity | 46.56 |
| Current Ratio | 2.09 |
| Total Cash | $403.63M |
| Total Debt | $230.49M |
| Free Cash Flow | $64.53M |
Source: Nexqual, July 25, 2026 at 11:16 UTC.
Financial Health Score (CYRX)
Nexqual rates Cryoport, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 11:16 UTC.
| Growth | Critical — Revenue -23% YoY (annual), sharp decline |
|---|---|
| Profitability | Mixed — Gross margin 47%, operating -20% |
| Balance Sheet | Strong — $404M cash vs $230M debt, net cash position |
| Cash Flow | Strong — FCF $65M, 37% margin |
| Efficiency | Critical — ROE -8%, ROA -2.5% |
Ownership (CYRX)
| Insider Ownership | +3.93% |
|---|---|
| Institutional Ownership | +96.46% |
| Shares Outstanding | 50.40M |
| Float | 40.85M |
| Short % of Float | +6.02% |
Source: Nexqual, July 25, 2026 at 11:16 UTC.
Leadership (CYRX)
Cryoport, Inc. is led by Jerrell W. Shelton (age 80), Chairman, President & CEO, per Nexqual as of July 25, 2026 at 11:16 UTC.
| Chairman, President & CEO | Jerrell W. Shelton (age 80) |
|---|---|
| Senior VP, CFO, Treasurer & Chief Administrative Officer | Robert S. Stefanovich MS (age 60) |
| Senior VP & Chief Scientific Officer | Mark W. Sawicki |
| Vice President of Corporate Development & Investor Relations | Thomas J. Heinzen |
| Vice President of Global Human Resources & Organizational Development | Kylie A. Crowe |
Major Backers & Investors (CYRX)
Notable institutional backers of Cryoport, Inc. include Cadian Capital Management, LP, Morgan Stanley, Millennium Management, according to Nexqual as of July 25, 2026 at 11:16 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Cadian Capital Management, LP | 9.48% |
| Morgan Stanley | 9.08% |
| Millennium Management | 5.89% |
| Fred Alger Management, LLC | 3.37% |
| MAK Capital One LLC | 2.82% |
| Mirova | 2.3% |
| Assenagon Asset Management S.A. | 2.29% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.89% |
| Vanguard Group | 8.3% |
| Geode Capital | 2.48% |
Source: Nexqual, July 25, 2026 at 11:16 UTC.
From Cryoport, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide.
- The company's Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry.
- Its Life Sciences Products segment manufactures, and sells cryogenic freezers, cryogenic dewars, and related ancillary accessories within the life science industry through direct sales or a distribution network.
- The company's products include Cryoport Express Shippers; Cryoport Elite; Cryoport Express Cryogenic HV3 Shipping System; Smartpak Condition Monitoring System and Tec4Med, an IoT-based monitoring solutions; and Cryoport accessories.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BLFS | BioLife Solutions, Inc. | USD 29.98 | ▼ 3.76% |
| CDNA | CareDx, Inc. | USD 37.14 | ▼ 1.69% |
| QTRX | Quanterix Corporation | USD 3.67 | ▼ 4.43% |
| IRTC | iRhythm Holdings, Inc. | USD 109.2 | ▲ 2.95% |
| ATRC | AtriCure, Inc. | USD 35.04 | ▲ 4.53% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 11:16 UTC. This page is informational and not investment advice.